French drugmaker Ipsen plans to acquire Cambridge-based Albireo in a deal worth about $952 million. Albierio is developing bile-acid modulators to treat pediatric and adult cholestatic liver diseases. The company was spun out from AstraZeneca in 2008 and is headquartered in Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The anticipated acquisition will enrich […]

The Janssen Pharmaceutical Companies of Johnson & Johnson, together with a consortium of global partners, have announced discontinuation of its HIV vaccine Phase 3 clinical trial based on the results of an independent data review by the study’s independent Data and Safety Monitoring Board (DSMB). The review determined that the HIV vaccine regimen was not […]

In early December, Seaport neighbors Vertex and Entrada announced a global collaboration focused on discovering and developing therapeutics for myotonic dystrophy type 1 (DM1). The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development. Entrada’s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics […]

Moderna has announced positive topline data from its Phase 3 trial of its vaccine candidate, mRNA-1345, targeting respiratory syncytial virus (RSV) in older adults. The primary efficacy endpoints have been met, including vaccine efficacy (VE) of 83.7% against RSV-associated lower respiratory tract disease. Based on these results, Moderna intends to submit for regulatory approval in […]

Waltham-based, clinical-stage biopharm CinCor is slated to be acquired by British pharmaceutical giant AstraZeneca. Founded in 2018, CinCor’s mission is to bring innovation to the pharmaceutical treatment of cardio-renal diseases. Its lead asset, baxdrostat, is in clinical development for the treatment of hypertension. Under the terms of the merger agreement, AstraZeneca will acquire all of […]

Eisai and Biogen have announced that the FDA has approved lecanemab-irmb (brand-named Leqembi in the U.S.) for the treatment of Alzheimer’s disease (AD) under the Accelerated Approval Pathway. The approval is based on Phase 2 data that demonstrated that Leqembi reduced the accumulation of amyloid beta (Aβ) plaque in the brain, a defining feature of […]